New preclinical tolebrutinib data demonstrated superior brain penetration and potency
New preclinical data demonstrated that tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), was the only…
Read More...
Read More...